🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What if we could flip the script? What if we could imagine a protein function and program a DNA molecule to encode that function? Noubar Afeyan discussing the work from the amazing team at Generate:Biomedicines Flagship Pioneering #CodeCon

Thanks @Fierce Biotech for honoring @Generate Biomedicines as one of the 2022 Fierce 15! This recognition is a testament to an amazing group of scientists that are fundamentally changing the way protein-based therapeutics are invented and leading the way in #generativebiology.

Proud of our colleagues Alexandra Snyder & Dinesh De Alwis for their commentary published today in Nature Medicine on the impact of clinical holds on smaller biotechs and how they ultimately benefit patients by leading to better medicines. ow.ly/mFsb50KM1BR

I am excited to join Diana Brainard, @AlexHoos, @SheilaMikhail, @PascalTouchon and @AnnalisaDAndrea this Thursday for an exciting discussion on advancing platform technologies @longwoodleaders.

Our co-founder Molly Gibson shares how we are increasingly making biology engineerable Generate:Biomedicines. We believe this will have a transformative impact on the patients we serve. Thanks Lydia The for highlighting our work.

Very exciting future for #proteindesign and #AI! Congratulations to Generate:Biomedicines on making the future possible. #Proteins are where life work gets done, and now we can make new ones.

Really enjoyed sitting down with Christine Heenan from Flagship Pioneering to discuss how Generate:Biomedicines is striving to bring better medicines to patients faster, including the critical role that culture plays in our success.

Unfortunately, cancer is personal for most of us. We are delighted to be partnering with one the preeminent cancer centers in MD Anderson Cancer Center to bring the power of generative AI to the fight against this disease.

Hear CEO of Generate:Biomedicines Mike Nally share updates on Generate:Biomedicines and why the company may have the Mona Lisa of molecules when it comes to treating mild-to-moderate asthma. Catch his full CEO Chat here: flagshippioneering.com/stories/ceo-ch… #FlagshipJPM #JPM24

Advances in artificial intelligence are at the heart of many of this year’s most exciting areas of technological innovation go.nature.com/48Zri0o

Join Grace Marden, one of our infectious disease scientists, at IAS–USA's CROI to hear about our groundbreaking antiviral research. Can’t attend? Check out the video below to see how we are using AI to ensure we are prepared for future pandemics.

The biotech brackets are out and a Cinderella story emerging with Generate:Biomedicines as a #13 seed. nam12.safelinks.protection.outlook.com/?url=https%3A%…

Researchers are using AI to create new proteins that do not exist in nature to fight diseases like cancer and asthma. cbsn.ws/3Qp03FL

Last night on 60 Minutes, Alex Snyder, MD, our EVP of R&D, sat down with Bill Whitaker to share our patient-first approach to healthcare: “We’re pushing the biology to make drugs that look like regular drugs, but function even better.” Watch here:

How do AI & drug development expertise reshape what’s possible? In a multi-target collaboration potentially valued at over $1 billion, we are partnering with Novartis to develop novel protein therapeutics that address critical medical needs. Learn more: generatebiomedicines.com/news/generateb…

A vaccine has essentially eliminated a dreadful form of cancer. Extraordinary.

Generative technologies have the potential to materially improve the standard of care for patients in a number of domains. GB-0895 is a great example of how our team at Generate:Biomedicines is focused on getting better medicines to patients, faster.

Always great to catch up with Christine Heenan and share how our team Generate:Biomedicines is leveraging the best of human and machine intelligence to learn from nature to make breakthrough medicines. We are in the early days of programmable biology and the future is bright.

GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted

Proud of the work our team Generate:Biomedicines is doing to help patients with COPD.